Giuseppe Loffredo
Overview
Explore the profile of Giuseppe Loffredo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loffredo G, Romano E, Maturo F
Stat Med
. 2025 Feb;
44(5):e10344.
PMID: 39930937
This article introduces a Random Survival Forest (RSF) method for functional data. The focus is specifically on defining a new functional data structure, the Censored Functional Data (CFD), for addressing...
2.
Galiero R, Loffredo G, Simeon V, Caturano A, Vetrano E, Medicamento G, et al.
PLoS One
. 2024 May;
19(5):e0296495.
PMID: 38713731
Background & Aims: SARS-Cov-2 infection manifests as a wide spectrum of clinical presentation and even now, despite the global spread of the vaccine, contagiousness is still elevated. The aim of...
3.
Palmiero G, Cesaro A, Galiero R, Loffredo G, Caturano A, Vetrano E, et al.
Diabetes Res Clin Pract
. 2023 Apr;
200:110686.
PMID: 37100231
Aims: Type 2 diabetes mellitus (T2DM) and heart failure are closely related entities and together determine an increased risk of mortality compared to patients suffering from only one of these...
4.
Nevola R, Feola G, Ruocco R, Russo A, Villani A, Fusco R, et al.
Int J Infect Dis
. 2023 Mar;
131:155-161.
PMID: 36944382
Objectives: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Methods: Prospective study including consecutive COVID-19...
5.
Caturano A, Galiero R, Loffredo G, Vetrano E, Medicamento G, Acierno C, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830859
Non-alcoholic fatty liver disease (NAFLD) comprises a heterogeneous group of metabolic liver diseases and is characterized by the presence of steatosis in at least 5% of hepatocytes. The aim of...
6.
Sasso F, Simeon V, Galiero R, Caturano A, De Nicola L, Chiodini P, et al.
Cardiovasc Diabetol
. 2022 Nov;
21(1):235.
PMID: 36344978
Background: Nephropathy in Diabetes type 2 (NID-2) study is an open-label cluster randomized clinical trial that demonstrated that multifactorial intensive treatment reduces Major Adverse Cardiac Events (MACEs) and overall mortality...
7.
Galiero R, Simeon V, Loffredo G, Caturano A, Rinaldi L, Vetrano E, et al.
J Clin Med
. 2022 Oct;
11(20).
PMID: 36294442
Background. Evidence has shown a close association between COVID-19 infection and renal complications in both individuals with previously normal renal function and those with chronic kidney disease (CKD). Methods. The...
8.
Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140374
Diabetic patients are frequently affected by coronary microvascular dysfunction (CMD), a condition consisting of a combination of altered vasomotion and long-term structural change to coronary arterioles leading to impaired regulation...
9.
Noris P, Marconi C, De Rocco D, Melazzini F, Pippucci T, Loffredo G, et al.
Br J Haematol
. 2017 May;
181(5):698-701.
PMID: 28466964
No abstract available.
10.
Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, et al.
Haematologica
. 2016 Jul;
101(11):1333-1342.
PMID: 27365488
ETV6-related thrombocytopenia is an autosomal dominant thrombocytopenia that has been recently identified in a few families and has been suspected to predispose to hematologic malignancies. To gain further information on...